The expression levels of immune checkpoints (CTLA-4, PD-1 and PD-L1) were investigated between the two risk groups and the low-risk COAD patients had significantly higher expression of CTLA4, PD-1 and PD-L1 than the high-risk patients. This evidence concerns the gene CTLA4 and colon adenocarcinoma.